Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Prepaid Assets (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Prepaid Assets for 14 consecutive years, with $22.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Prepaid Assets rose 101.99% year-over-year to $22.8 million, compared with a TTM value of $22.8 million through Sep 2025, up 101.99%, and an annual FY2024 reading of $17.7 million, up 189.15% over the prior year.
  • Prepaid Assets was $22.8 million for Q3 2025 at Heron Therapeutics, up from $17.4 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $27.6 million in Q3 2021 and bottomed at $6.1 million in Q4 2023.
  • Average Prepaid Assets over 5 years is $15.0 million, with a median of $13.1 million recorded in 2022.
  • The sharpest move saw Prepaid Assets plummeted 72.4% in 2022, then skyrocketed 302.4% in 2025.
  • Year by year, Prepaid Assets stood at $13.0 million in 2021, then increased by 7.71% to $14.0 million in 2022, then tumbled by 56.18% to $6.1 million in 2023, then skyrocketed by 189.15% to $17.7 million in 2024, then increased by 29.12% to $22.8 million in 2025.
  • Business Quant data shows Prepaid Assets for HRTX at $22.8 million in Q3 2025, $17.4 million in Q2 2025, and $26.5 million in Q1 2025.